Of major importance to diabetic patients is the effect of SGLT-2 inhibitors on the course of cardiovascular complications to which they are particularly predisposed, such as acute coronary syndromes, especially acute myocardial infarction (AMI). This evidence concerns the gene SLC5A2 and acute coronary syndrome.